Lin Patrick 4

What Happened
Lin Patrick, Chief Business & Strategy Officer at Processa Pharmaceuticals (PCSA), purchased 1,369 shares in an open‑market transaction on May 15, 2026. The shares were acquired at $2.97 per share for a total of about $4,066. This was a straight purchase (transaction code P), which is a direct insider buy rather than a sale or option exercise.

Key Details

• Transaction date: 2026-05-15 (open market purchase)
• Price and amount: 1,369 shares at $2.97 each; total ≈ $4,066
• Transaction code: P (purchase)
• Shares owned after transaction: not disclosed in this filing
• Timeliness: Filed on 2026-05-19 (report covers 2026-05-15); filing date appears timely under standard Form 4 rules
• Footnote: Corrects an immaterial error in a prior Form 4 (filed May 1, 2026) — the April 30, 2026 purchase price was $2.71 (not $2.69), reducing that prior purchase by 11 shares

Context
Purchases by company officers are often viewed as a more informative signal than sales because they involve personal cash outlay; this filing documents a modest open‑market buy. No 10b5‑1 plan, option exercise, gift, or tax withholding is reported in this Form 4.